SCHEMBL23835355

SCHEMBL23835355

O=C(O)C(/N=C/c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP2D6 P10635 1/20 0.43
SRC P12931 1/20 0.43
LMNA P02545 4/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
PLA2G7 Q13093 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23835356 1.00 CYP1A2 (0.46) CYP1A2MEN1KMT2ACYP2D6SRC
SCHEMBL11543708 0.87 LMNA (0.45) CYP1A2MEN1KMT2ACYP2D6SRC
SCHEMBL6073037 0.87 LMNA (0.45) CYP1A2MEN1KMT2ACYP2D6SRC
SCHEMBL9788843 0.87 LMNA (0.45) CYP1A2MEN1KMT2ACYP2D6SRC
SCHEMBL6073029 0.87 LMNA (0.45) CYP1A2MEN1KMT2ACYP2D6SRC
SCHEMBL6073034 0.87 LMNA (0.45) CYP1A2MEN1KMT2ACYP2D6SRC
SCHEMBL11690248 0.84 CYP1A2 (0.50) CYP1A2MEN1KMT2ALMNAALDH1A1
SCHEMBL2984290 0.81 KMT2A (0.51) MEN1KMT2ALMNACA1CA2
SCHEMBL9734293 0.81 KMT2A (0.51) MEN1KMT2ALMNACA1CA2
SCHEMBL2984292 0.81 KMT2A (0.51) MEN1KMT2ALMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 EP disclosed
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2021-09-30 US disclosed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO disclosed
CN-107667103-A Amino ester derivatives 奇斯药制品公司 2018-02-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 CYP1A2 1952/4885MEN1 3890/4885KMT2A 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.